Star Seyedkazemi

Star Seyedkazemi, PharmD is Adverum’s chief development officer responsible for the company’s development programs including global clinical operations, program strategy and project management. She has over 20 years of experience in small molecule and biologic research and development, program leadership, portfolio management, U.S. and global medical affairs and clinical care. Dr. Seyedkazemi most recently served as vice president portfolio management for research and development at Pliant Therapeutics. Before joining Pliant, Dr. Seyedkazemi served as associate vice president at AbbVie, where she was responsible for clinical and global program leadership for the development of cenicriviroc for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Before that, Dr. Seyedkazemi held roles of increasing responsibility at several companies and across multiple therapeutic areas, including fibrosis, NASH, hepatitis C and HIV at AbbVie, Allergan (acquired by AbbVie), Tobira Therapeutics (acquired by Allergan), Gilead Sciences, Johnson & Johnson and Abbot Laboratories, preceded by 7 years in HIV clinical care and research. Dr. Seyedkazemi earned her Doctor of Pharmacy degree at Nova Southeastern University (NSU) and completed a HIV/Infectious Disease residency at NSU and Broward Health in Fort Lauderdale, FL.